Botulinum toxin A longer acting - Ipsen
Alternative Names: IPN-10200; Long acting toxin - Ipsen; Longer-acting neurotoxin - Ipsen; modified recombinant Botulinum Neurotoxin/A; mrBoNT/A; mrBoNT/ABLatest Information Update: 28 Apr 2025
At a glance
- Originator Ipsen
- Class Analgesics; Anti-inflammatories; Antiarrhythmics; Antidepressants; Antimigraines; Antipruritics; Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Eye disorder therapies; Foot disorder therapies; Muscle relaxants; Recombinant proteins; Skin disorder therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Membrane transport protein modulators; Neuromuscular blocking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Migraine
- Phase I/II Glabellar lines; Muscle spasticity
Most Recent Events
- 22 Apr 2025 Ipsen plans a phase II trial for Torticollis (In adults) in April 2025 (IM) (NCT06937931)
- 10 Oct 2024 Phase-II clinical trials in Migraine (Prevention, Treatment-experienced) in USA (IM) (NCT06625060)
- 07 Oct 2024 Ipsen plans the MERANTI phase II trial for Migraine (Prevention, Treatment-experienced) (IM, Injection) in October 2024 (NCT06625060)